Table 1.
Clinical characteristics in the enrolled patients*.
| (n = 38) | |
|---|---|
| Age, years | 52 (39–58) |
| Female, number (%) | 28 (74) |
| PM, DM, and CADM, number | 12, 14, 12 |
| Disease duration, month | 4 (2–7) |
| Interstitial lung disease, number (%) | 21 (55) |
| Rapidly progressive, number (%) | 10 (26) |
| Chronic, number (%) | 11 (29) |
| Myositis-specific autoantibodies, number (%) | |
| Anti-ARS | 12 (32) |
| Anti-Mi-2 | 1 (3) |
| Anti-MDA-5 | 10 (26) |
| Anti-SRP | 2 (5) |
*Thirty-eight patients were enrolled in the present study.
Values are median (interquartile range).
PM: polymyositis; DM: dermatomyositis; CADM: clinically amyopathic DM; ARS: aminoacyl-tRNA synthetase; MDA-5: melanoma differentiation-associated gene 5; and SRP: signal recognition particle.